Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis
COR167 inhibits proliferation of normal and MS immune cells. COR167 shifts Th1 towards Th2 phenotype and down-regulates IL-4, IL-5 and Th17 phenotype. COR167 reduces in vitro cell trafficking through human brain endothelium. Cannabinoid CB2 receptor is a pharmacological target to counteract neuroinflammation.